2. CK-2127107 (CK-107)
In collaboration with Astellas, Cytokinetics is developing CK-2127107 (CK-107), a new skeletal muscle troponin activator as a potential treatment for people living with SMA. CK-107 has completed five Phase 1 clinical trials in healthy volunteers, and is currently the subject of two Phase 2 clinical trials.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?